Drug intelligence / Profile preview

L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide

Development stage
Unknown
Modality
Peptides, Small Molecules
01

Overview

L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide is an experimental small molecule compound classified as a dipeptide derivative. It is primarily used in biomedical research and drug development as an inhibitor of nitric oxide synthase enzymes. The compound acts by inhibiting the production of nitric oxide (NO), a key signaling molecule involved in various physiological processes including neurotransmission and vascular regulation. Its main mechanism involves competitive inhibition at the active site of nitric oxide synthase, particularly targeting neuronal NOS (NOS1). This agent has not been approved for clinical use and remains at the experimental stage[1][3][6].

Other names
L-N(OMEGA)-NITROARGININE-2,4-L-DIAMINOBUTYRIC AMIDE(2S)-2-amino-N-((1S)-3-amino-1-carbamoylpropyl)-5-(N'-nitrocarbamimidamido)pentanamide(2S)-2-amino-N-[(1S)-3-amino-1-carbamoylpropyl]-5-(N'-nitrocarbamimidamido)pentanamide
02

Targets

NOS1 (nNOS)

Beyond the preview

Go deeper on L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call